Technical Analysis for ARGSQ - Argos Therapeutics

Grade Last Price % Change Price Change
grade D 0.0457 0.00% 0.0000
ARGSQ closed unchanged on Friday, August 16, 2019, on 62 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical ARGSQ trend table...

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%

Older signals for ARGSQ ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. As of February 13, 2019, Argos Therapeutics Inc. operates as a subsidiary of Genexine Inc. and SCM Lifescience Co.
Cancer Infectious Diseases Treatment Of Cancer Cancer Immunotherapy Immunotherapies Ags 004 Arcelis Immunotherapies Based On Its Proprietary Technology Metastatic Renal Cell Carcinoma
Is ARGSQ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.1045
52 Week Low 0.019
Average Volume 10,939
200-Day Moving Average 0.0
50-Day Moving Average 0.0647
20-Day Moving Average 0.0613
10-Day Moving Average 0.0583
Average True Range 0.0145
ADX 44.56
+DI 5.037
-DI 19.8025
Chandelier Exit (Long, 3 ATRs ) 0.0215
Chandelier Exit (Short, 3 ATRs ) 0.0886
Upper Bollinger Band 0.0746
Lower Bollinger Band 0.048
Percent B (%b) -0.09
BandWidth 43.393149
MACD Line -0.0037
MACD Signal Line -0.0016
MACD Histogram -0.0021
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0457
Resistance 3 (R3) 0.0457 0.0457 0.0457
Resistance 2 (R2) 0.0457 0.0457 0.0457 0.0457
Resistance 1 (R1) 0.0457 0.0457 0.0457 0.0457 0.0457
Pivot Point 0.0457 0.0457 0.0457 0.0457 0.0457
Support 1 (S1) 0.0457 0.0457 0.0457 0.0457 0.0457
Support 2 (S2) 0.0457 0.0457 0.0457 0.0457
Support 3 (S3) 0.0457 0.0457 0.0457
Support 4 (S4) 0.0457